REGN — Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenues: $3.8 billion, a 1% increase year-over-year.
• Net Income: $1.3 billion, with diluted EPS of $11.83.
• Dupixent Sales: $4.9 billion globally, up 26% year-over-year; U.S. sales increased 28%.
• Libtayo Sales: $365 million globally, a 24% increase on a constant currency basis; U.S. sales grew 12%.
• EYLEA HD Sales: $431 million in the U.S., an all-time high, driven by unit demand growth despite pricing pressures.
• EYLEA Sales: $681 million in the U.S., a 10% decline quarter-over-quarter.
• R&D Expenses: $1.3 billion, reflecting ongoing investments in pipeline development.
• Free Cash Flow: $3.2 billion for the first nine months of 2025.
• Share Repurchases: $2.8 billion in 2025, with an expectation to return approximately $4 billion to shareholders through dividends and buybacks.

2. Strategic Updates and Business Highlights

• Dupixent: Now approved for 8 diseases, with over 1.3 million patients treated globally. Strong growth expected to continue due to its broad applicability and efficacy.
• Libtayo: Recently approved for high-risk adjuvant cutaneous squamous cell carcinoma, with a promising launch underway.
• EYLEA HD: Strong demand growth noted, but affordability issues and competitive pricing pressures remain challenges.
• Pipeline Progress: Positive Phase III data announced for multiple programs, including Dupixent and various allergy treatments. Significant advancements in oncology and rare diseases were highlighted.
• Government Discussions: Ongoing constructive discussions with the U.S. government to lower drug costs while preserving innovation.

3. Forward Guidance and Outlook

• 2025 Guidance: Updated and narrowed financial guidance provided, with expectations for continued growth in key products.
• 2026 R&D Expense: Anticipated mid-teens percentage increase to support ongoing pipeline development.
• EYLEA HD: Expected moderate to high single-digit sequential demand growth as label enhancements are awaited.

4. Bad News, Challenges, or Points of Concern

• EYLEA Sales Decline: A 10% decline in EYLEA sales quarter-over-quarter, attributed to competitive pressures and affordability issues.
• Regulatory Setbacks: A complete response letter from the FDA regarding EYLEA HD's prefilled syringe application due to unresolved inspection findings at a third-party facility.
• Affordability Program: A disappointing matching contribution of under $1 million to the Good Days fund, raising concerns about the effectiveness of current initiatives to address patient affordability.

5. Notable Q&A Insights

• EYLEA Strategy: Management refrained from disclosing specific competitive strategies regarding pricing and discounts, citing ongoing competitive dynamics.
• Manufacturing and Regulatory Concerns: Emphasis on the need for improved manufacturing capabilities, particularly in filling, to avoid future regulatory issues.
• Pipeline Acceleration: Discussions on the potential for expedited development timelines for promising therapies, particularly in oncology and hematology.
• Market Dynamics: Insights into the evolving landscape of inventory policies in clinics and the influence of private equity on treatment choices were discussed, indicating a complex competitive environment.

Overall, Regeneron demonstrated strong commercial execution and pipeline advancements in Q3 2025, but faced challenges related to pricing pressures and regulatory hurdles that could impact future growth.